SCHEMBL4920158

SCHEMBL4920158

O=C(Nc1ccc(Cl)cc1)Nc1ccc(-n2cccn2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.68
KMT2A Q03164 7/20 0.55
MEN1 O00255 6/20 0.55
F10 P00742 1/20 0.54
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.51
MAPT P10636 6/20 0.50
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
NAMPT P43490 1/20 0.50
MDM2 Q00987 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 1/20 0.47
CNR1 P21554 1/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920444 0.88 CNR1 (0.60) NOTUMKMT2AMEN1RAB9ACNR1
SCHEMBL11112302 0.84 TNIK (0.56) NOTUMKMT2AF10MAPTALDH1A1
SCHEMBL182132 0.82 NOTUM (1.00) NOTUMKMT2AMEN1F10MAPT
SCHEMBL15742711 0.82 NOTUM (0.55) NOTUMF10RAB9ANPC1MAPT
SCHEMBL4915722 0.77 DRD2 (0.56) KMT2AMEN1RAB9ANPC1HTT
SCHEMBL31157850 0.77 RXFP1 (0.52) NOTUMKMT2AF10RAB9ANPC1
SCHEMBL3377974 0.77 RAB9A (0.55) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL4919323 0.76 MAPT (0.56) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL13701946 0.75 GAA (0.63) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL8769758 0.75 ALDH1A1 (0.55) KMT2AMEN1F10RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NOTUM 1731/4885KMT2A 1905/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NOTUM 1731/4885KMT2A 1905/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.